Road to Victories

Chuck Wakefield Patient

Chuck is our “media darling” as he is a 73 yr. old patient who takes on incredibly difficult endeavors on behalf of the MMRF. His first event with us was climbing Kilimanjaro at the age of 70 and then did the full cross country R2V ride last fall. “I am a patient, first diagnosed with MM on routine physical exam in December 2003, with a rapidly developing case. The initial outlook wasn’t that great, and I had 8 months of intensive chemo, followed by a bone marrow transplant in August 2004. With a brand new immune system, I was 12 years old August 12, 2016, and am miraculously in complete remission for the past year and a half.”

I’m one of the Lucky Ones

Chuck Wakefield

I'm mindful of how many myeloma patients are having a tough time. I am one of the lucky ones.

05/10/2019

The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. Learn more and sign up to receive news and resources from the MMRF.

Learn More

Sponsored by

At Janssen Oncology, we’re shaping the future of cancer treatment. In the process, we’re striving to change expectations of what a cancer diagnosis means. Our purpose is driven by an urgency and commitment to bringing transformational cancer solutions to the people who need them. Passionate about our work, we are driven by the personal connection many of us share with the disease. With our partners, we focus on delivering solutions that make a positive impact on human health. We are part of Janssen Biotech, Inc., and the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Janssen Oncology

Click below to learn more about a treatment option for multiple myeloma. If you’re also interested in getting more information from Janssen, sign up for ongoing communications.

Learn More